Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab +/- Tremelimumab in Resectable Malignant Pleural Mesothelioma
NCT02592551Phase 2Completed
- Sponsor
- Baylor College of Medicine
- Start
- May 2016
- Primary completion
- Aug 2019
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of durvalumab in malignant pleural mesothelioma (MPM) (3 arms), sponsored by Baylor College of Medicine. Primary endpoint: Change in Ratio of Intratumoral Cytotoxic T Cells to Regulatory T Cells. Started May 2016; status: completed.
02
Drugs
durvalumab
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT02592551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02592551.